Ignite Creation Date:
2025-12-25 @ 1:41 AM
Ignite Modification Date:
2026-02-25 @ 8:31 PM
Study NCT ID:
NCT02822794
Status:
COMPLETED
Last Update Posted:
2018-11-14
First Post:
2016-06-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
Sponsor:
Gilead Sciences
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
GS-US-342-3921
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None